Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Nov 03, 2021 3:03pm
431 Views
Post# 34083452

RE:Catalyst

RE:Catalyst
Doccole wrote: What catalysts will help this stock grow? Insider buys bumped it, now back to stagnant.  Thoughts?


If you are looking for potential items that could move the stock ... here are a few things to think about ...
1. 346 (acute) fast-track application and then a further acceptance from FDA 60 days later (assuming we get it)
2. 352 details to emerge - large unmet need in acute ???  Also any fast-track to go with that ???
3. chronic regimen update and further timelines on development
4. IBD candidate selection - and next steps
5. New drug development update - new drugs added to the mix
6. Sale of CITA
7. Further partnering with Nuance on acute - maybe Nuance doubles down - unlikely but what if the two sides can come to some agreement to add acute

End of November or early December corporate update (maybe we can still expect this) with a new presentation to cover some of the above items ... or other missed items.

Just some thoughts to begin a conversation.
<< Previous
Bullboard Posts
Next >>